These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16056005)

  • 41. Chairman of the Joint Formulary Committee, British National Formulary.
    Kendall M
    Clin Med (Lond); 2009 Aug; 9(4):349-52. PubMed ID: 19728509
    [No Abstract]   [Full Text] [Related]  

  • 42. Operation, formulary decision-making activities of a P & T Committee in a managed care setting.
    Adams J; Richardson J
    Hosp Formul; 1991 Apr; 26(4):291-4, 300-1. PubMed ID: 10109798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacoeconomic analysis in formulary decisions: an international perspective.
    Johnson JA; Bootman JL
    Am J Hosp Pharm; 1994 Oct; 51(20):2593-8. PubMed ID: 7847423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
    Weekes LM; Day RO
    Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Formularies in integrated health systems: Sharp HealthCare.
    Rizos AL; Levy E; Furnier J; Crowley K
    Am J Health Syst Pharm; 1996 Feb; 53(3):274-8. PubMed ID: 8808022
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managed care pharmacy, socioeconomic assessments and drug adoption decisions.
    Lyles A; Luce BR; Rentz AM
    Soc Sci Med; 1997 Aug; 45(4):511-21. PubMed ID: 9226777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Applying Lean Six Sigma to improve medication management.
    Nayar P; Ojha D; Fetrick A; Nguyen AT
    Int J Health Care Qual Assur; 2016; 29(1):16-23. PubMed ID: 26771058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of HMO formulary adoption decisions.
    Dranove D; Hughes EF; Shanley M
    Health Serv Res; 2003 Feb; 38(1 Pt 1):169-90. PubMed ID: 12650387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diabetes prevalence and hospital and pharmacy use in the Veterans Health Administration (1994). Use of an ambulatory care pharmacy-derived database.
    Pogach LM; Hawley G; Weinstock R; Sawin C; Schiebe H; Cutler F; Zieve F; Bates M; Repke D
    Diabetes Care; 1998 Mar; 21(3):368-73. PubMed ID: 9540017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Formulary-control procedures in a staff-model health maintenance organization.
    Lyon RA
    Am J Hosp Pharm; 1990 Feb; 47(2):340-2. PubMed ID: 2106782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should Medicare adopt the Veterans Health Administration formulary?
    Frakt AB; Pizer SD; Feldman R
    Health Econ; 2012 May; 21(5):485-95. PubMed ID: 21506191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reducing outpatient costs of nonsteroidal antiinflammatory drugs at a Department of Veterans Affairs teaching hospital.
    Drexler PG; Lambdin CS
    J Pharm Technol; 1993; 9(1):10-3. PubMed ID: 10123760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A pharmacoeconomics and formulary management collaborative project to teach decision analysis principles.
    Cavanaugh TM; Buring S; Cluxton R
    Am J Pharm Educ; 2012 Aug; 76(6):115. PubMed ID: 22919091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Physician satisfaction with formulary policies: is it access to formulary or nonformulary drugs that matters most?
    Glassman PA; Good CB; Kelley ME; Bradley M; Valentino M
    Am J Manag Care; 2004 Mar; 10(3):209-16. PubMed ID: 15032258
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
    Anis AH; Gagnon Y
    Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging factors shaping the future of the Veterans' Health Administration: a strategic analysis.
    Rivers PA; Glover SH; Agho A
    Health Serv Manage Res; 2002 Feb; 15(1):27-39. PubMed ID: 11854993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug benefits in managed care: seeking ethical guidance from the formulary?
    Fins JJ
    J Am Geriatr Soc; 1998 Mar; 46(3):346-50. PubMed ID: 9514384
    [No Abstract]   [Full Text] [Related]  

  • 59. The bleeding edge of decision making in managed health care--Kaiser-Permanente's model for formulary development.
    Campen D
    Value Health; 2002; 5(5):383-9. PubMed ID: 12201855
    [No Abstract]   [Full Text] [Related]  

  • 60. A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses.
    Levy J; Rosenberg M; Vanness D
    Value Health; 2018 Jun; 21(6):677-684. PubMed ID: 29909872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.